<DOC>
	<DOC>NCT00004375</DOC>
	<brief_summary>OBJECTIVES: I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.</brief_summary>
	<brief_title>Ultraviolet Light Therapy for Systemic Lupus Erythematosus</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Treatment with ultraviolet A-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. The dose and frequency are progressively decreased over the next 9 weeks.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Patients ages 15 to 70 with symptomatic systemic lupus erythematosus meeting American Rheumatism Association criteria and normal controls Prior/Concurrent Therapy No requirement for tetracycline or other photosensitizing drugs</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>arthritis &amp; connective tissue diseases</keyword>
	<keyword>immunologic disorders and infectious disorders</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
</DOC>